388 results on '"Shinkai, Masaharu"'
Search Results
2. Macrolides and Immunomodulation: Today and the Future
3. Diagnostic utility of pharyngeal follicular structures in COVID-19: A large-scale cross-sectional study
4. Effectiveness and duration of additional immune defense provided by SARS-CoV-2 infection before and after receiving the mRNA COVID-19 vaccine BNT162b2
5. Burden of respiratory syncytial virus, human metapneumovirus and influenza virus infections in Japanese adults in the Hospitalized Acute Respiratory Tract Infection study
6. Pulmonary function and chest CT abnormalities 3 months after discharge from COVID-19, 2020–2021: A nation-wide multicenter prospective cohort study from the Japanese respiratory society
7. Phase III study of bilayer sustained-release tramadol tablets in patients with cancer pain: a double-blind parallel-group, non-inferiority study with immediate-release tramadol capsules as an active comparator
8. A case of reinfection with a different variant of SARS-CoV-2: case report
9. Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain
10. Nationwide survey in Japan of the causative diseases of bloody sputum and hemoptysis in departments of respiratory medicine at university hospitals and core hospitals
11. Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19
12. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults
13. Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization
14. Possibility of underestimation of COVID-19 prevalence by PCR and serological tests
15. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
16. SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype
17. Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study
18. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
19. Correction: A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
20. Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine
21. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
22. The Japanese respiratory society guidelines for the management of cough and sputum (digest edition)
23. Repeated Omicron exposures redirect SARS-CoV-2–specific memory B cell evolution toward the latest variants.
24. Comparison of liver fibrosis scores and fatty liver on computed tomography as risk factors for severity of COVID‐19.
25. Surveillance of seasonal influenza viruses during the COVID‐19 pandemic in Tokyo, Japan, 2018–2023, a single‐center study
26. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study
27. Cystic Fibrosis, Primary Ciliary Dyskinesia, and Diffuse Panbronchiolitis: Hereditary and Non-hereditary—What Are the Roles of Genetic Factors in the Pathogenesis of These Diseases?
28. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
29. Surveillance of seasonal influenza viruses during the COVID-19 pandemic in Tokyo, Japan, 2018--2023, a single-center study
30. Findings from a discontinued clinical trial of favipiravir in high-risk patients with early-onset COVID-19
31. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma
32. Diffuse Panbronchiolitis
33. High Fever, Wide Distribution of Viral Pneumonia, and Pleural Effusion are More Critical Findings at the First Visit in Predicting the Prognosis of COVID-19: A Single Center, retrospective, Propensity Score-Matched Case–Control Study
34. Digital PCR assay detection of circulating Mycobacterium tuberculosis DNA in pulmonary tuberculosis patient plasma
35. Solithromycin inhibits IL-13-induced goblet cell hyperplasia and MUC5AC, CLCA1, and ANO1 in human bronchial epithelial cells
36. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults
37. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
38. Heterologous booster immunization with SARS-CoV-2 spike protein after mRNA vaccine elicits durable and broad antibody responses
39. Mortality and severity evaluation by routine pneumonia prediction models among Japanese patients with 2009 pandemic influenza A (H1N1) pneumonia
40. Nonepisodic angioedema with eosinophilia following a rose-thorn prick injury
41. Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.
42. High Fever, Wide Distribution of Viral Pneumonia, and Pleural Effusion are More Critical Findings at the First Visit in Predicting the Prognosis of COVID-19: A Single Center, retrospective, Propensity Score-Matched Case–Control Study.
43. Regulatory role of heme oxygenase-1 in silica-induced lung injury
44. Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study
45. Viral load and timing of infection define neutralization diversity to SARS-CoV-2 infection
46. One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study
47. One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study.
48. Detection of silent infection of severe acute respiratory syndrome coronavirus 2 by serological tests
49. SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine
50. Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.